2023 may not be the best year for the pharmaceutical industry, but Novo Nordisk's Ozempic (Smegallutide) is among the most popular drugs such as Keytruda, Dupixent and Eliquis, marking a new era for the treatment of metabolic diseases. Novo Nordisk's sales grew by more than a third in 2023. Obesity-focused Wegovy (Smeaglutide) and Lilly's Mounjaro (tirparatide) were also ranked in the top 50. Furthermore, in 2023, tiparatide was granted FDA approval as treatment for obesity, and in March 2024, simegallutide received an extended label for cardiovascular risk reduction.
The rise of drugs for metabolic diseases highlights the increasing global burden of obesity and diabetes. Ozempic2023 With annual sales of $13.9 billion, up 38%, GLP-1 seems poised to play an important role in treating metabolic diseases.
The table below shows explosive sales growth of Mounjaro (tiparatide), a GLP-1 receptor agonist present in the chart below along with Zepbound (an obesity-targeted version of the same drug).
Note: The Mounjaro was launched in mid-2022, with only two quarters of sales data. To normalize its performance, the visual map calculates sales for 2022 by doubling its half-year sales figure. Growth rate and bubble size are calculated using this calculated 2022 sales value.
Despite significant advances in the treatment of metabolic diseases, oncology drugs continue to dominate the list of popular drugs. Since mid-2015, Keytruda has maintained its position as the top-selling drug product as a strongly selling cancer immunotherapy, with sales of $25 billion, an increase of 19% from 2022. Other oncology treatments, such as Darzalex, Opdivo, and Tagrisso, have also experienced growth.
Oncology and immunology continue to dominate the pharmaceutical industry pattern below the figure provides 2023 top 50 drug sales categories of visualization, highlights the increasing importance of metabolic therapy, but also shows the continued dominance of oncology, accounting for more than a quarter of the top best-selling drug sales, immunology accounted for more than one fifth.
Looking at the global drug sales data for 2022 to 2023, it is clear that oncology is leading in the pharmaceutical industry. Over the past two years, sales of oncology drugs accounted for nearly one-third of the world's top 50 drugs. While oncology continues to dominate, sales of inflammatory and immunotherapeutic drugs and metabolic disease treatments also show strong growth momentum.
Treatment drugs for metabolic diseases, especially those represented by GLP-1 receptor agonists, have made remarkable achievements in the treatment of type 2 diabetes and obesity. As research continues, these drugs show great potential in the treatment of diseases related to metabolic disorders, such as cardiovascular disease and metabolic-related steatohepatitis, indicating even more substantial market returns in the future.
In the field of inflammation and immunotherapy, some emerging drugs such as Skyrizi (risankizumab-rzaa) have come to emerge as patents for biologics such as Seumele (Humira) expire and competition for biosimilars has intensified. In addition, with the maturity of tumor immunotherapy technologies, such as CAR-T therapy, the application of these technologies is gradually expanding to the field of immune disease treatment, indicating that this field will usher in the double breakthrough of scientific discovery and commercial success.
In general, the development of the pharmaceutical industry shows a trend of diversification, and oncology, metabolic disease treatment and inflammation / immunotherapy will jointly promote the growth of the pharmaceutical market in the next few years. With the continuous development of new drugs and the expansion of existing drug indications, the pharmaceutical industry will continue to bring more treatment options and hope for patients.
Sales of the top 50 drugs in 2023
参考文献：
1. BrianBuntz，Best-sellingpharmaceuticalsof2023revealashiftinpharmalandscape
2. KrebsQin，肿瘤、代谢、免疫，三分天下之势已定
The company's product recommendation
1.284461-73-0 https://www.bicbiotech.com/product_detail.php?id=4383
2.223673-61-8 https://www.bicbiotech.com/product_detail.php?id=5315
3.2628280-40-8 https://www.bicbiotech.com/product_detail.php?id=1901
4.119831-72-0 https://www.bicbiotech.com/product_detail.php?id=5317
5.776277-76-0 https://www.bicbiotech.com/product_detail.php?id=5318
